Telmisartan prevented cognitive decline partly due to PPAR-γ activation

Biochemical and Biophysical Research Communications

Volumn 375, Issue 3, 2008, Pages 446-449

  Mogi, Masaki ^a   Li, Jian Mei ^a   Tsukuda, Kana ^a   Iwanami, Jun ^a   Min, Li Juan ^a   Sakata, Akiko ^a   Fujita, Teppei ^a   Iwai, Masaru ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer disease; Amyloid ; Angiotensin II receptor blocker; PPAR ; Telmisartan

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; COGNITION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MOUSE; MALE; MENTAL DETERIORATION; MOUSE; NONHUMAN; PREVENTION AND CONTROL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

AMYLOID BETA-PROTEIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANILIDES; ANIMALS; BENZIMIDAZOLES; BENZOATES; BRAIN; COGNITION DISORDERS; LOSARTAN; MALE; MICE; MICE, INBRED STRAINS; PPAR GAMMA;

MUS;

EID: 50849089332     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.08.032     Document Type: Article

References (21)

1. Qiu C., Winblad B., and Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4 (2005) 487-499
2. Birkenhager W.H., Forette F., Seux M.L., Wang J.G., and Staessen J.A. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch. Intern. Med. 161 (2001) 152-156
3. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
4. Libby P., and Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am. J. Cardiol. 99 (2007) 27B-40B
5. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., and Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 280 (2005) 21453-21462
6. Wang N., Verna L., Chen N.G., Chen J., Li H., Forman B.M., and Stemerman M.B. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 277 (2002) 34176-34181
7. Klotz L., Sastre M., Kreutz A., Gavrilyuk V., Klockgether T., Feinstein D.L., and Heneka M.T. Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J. Neurochem. 86 (2003) 907-916
8. Camacho I.E., Serneels L., Spittaels K., Merchiers P., Dominguez D., and De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24 (2004) 10908-10917
9. Wada K., Nakajima A., Katayama K., Kudo C., Shibuya A., Kubota N., Terauchi Y., Tachibana M., Miyoshi H., Kamisaki Y., Mayumi T., Kadowaki T., and Blumberg R.S. Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J. Biol. Chem. 281 (2006) 12673-12681
10. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., and Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199 (2006) 265-273
11. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., and Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950-958
12. Nitta A., Itoh A., Hasegawa T., and Nabeshima T. Beta-amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 170 (1994) 63-66
13. Tajima H., Kawasumi M., Chiba T., Yamada M., Yamashita K., Nawa M., Kita Y., Kouyama K., Aiso S., Matsuoka M., Niikura T., and Nishimoto I. A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J. Neurosci. Res. 79 (2005) 714-723
14. Krege J.H., Hodgin J.B., Hagaman J.R., and Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25 (1995) 1111-1115
15. Mogi M., Li J.M., Iwanami J., Min L.J., Tsukuda K., Iwai M., and Horiuchi M. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 48 (2006) 141-148
16. Li J.M., Mogi M., Iwanami J., Min L.J., Tsukuda K., Sakata A., Fujita T., Iwai M., and Horiuchi M. Temporary pretreatment with angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage via increase in capillary density. Stroke 39 (2008) 2029-2036
17. Wang J., Ho L., Chen L., Zhao Z., Zhao W., Qian X., Humala N., Seror I., Bartholomew S., Rosendorff C., and Pasinetti G.M. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117 (2007) 3393-3402
18. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., and Feinstein D.L. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22 (2002) 2434-2442
19. Ferrario C.M., and Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am. J. Cardiol. 98 (2006) 121-128
20. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 103 (2006) 443-448
21. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., Tschanz J.T., Mayer L.S., Welsh-Bohmer K.A., and Breitner J.C. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 63 (2006) 686-692